We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing.
- Authors
Roy-Chowdhuri, Sinchita; de Melo Gagliato, Debora; Routbort, Mark J.; Patel, Keyur P.; Singh, Rajesh R.; Broaddus, Russell; Lazar, Alexander J.; Sahin, Aysegul; Alvarez, Ricardo H.; Moulder, Stacy; Wheler, Jennifer J.; Janku, Filip; Gonzalez-Angulo, Ana M.; Chavez-MacGregor, Mariana; Valero, Vicente; Ueno, Naoto T.; Mills, Gordon; Mendelsohn, John; Hui Yao; Aldape, Kenneth
- Abstract
<bold>Objectives: </bold>The advent of next-generation sequencing (NGS) platforms in the realm of clinical molecular diagnostics provides multigene mutational profiling through massively parallel sequencing.<bold>Methods: </bold>We analyzed 415 breast carcinoma samples from 354 patients using NGS in known hotspots of 46 commonly known cancer-causing genes.<bold>Results: </bold>A total of 281 somatic nonsynonymous mutations were detected in 62.1% of patients. TP53 was most frequently mutated (38.8%), followed by PIK3CA (31.7%), AKT1 (6%), and ATM (3.9%), with other mutations detected at a lower frequency. When stratified into clinically relevant therapeutic groups (estrogen receptor [ER]/progesterone receptor [PR]+ human epidermal growth factor receptor 2 [HER2]-, ER/PR+HER2+, ER/PR-HER2+, ER/PR/HER2-), each group showed distinct mutational profiles. The ER/PR+HER2- tumors (n = 132) showed the highest frequency of PIK3CA mutations (38%), while the triple-negative tumors (n = 64) had a significantly higher number of TP53 mutations (62%). Of the 61 patients tested for both primary and metastatic tumors, concordant results were seen in 47 (77%) patients, while 13 patients showed additional mutations in the metastasis.<bold>Conclusions: </bold>Our results indicate that breast cancers may harbor potentially actionable mutations for targeted therapeutics. Therefore, NGS-based mutational profiling can provide useful information that can guide targeted cancer therapy.
- Subjects
PROTEIN metabolism; BREAST tumors; CELL receptors; GENETIC mutation; PROTEINS; RESEARCH funding; SEQUENCE analysis
- Publication
American Journal of Clinical Pathology, 2015, Vol 144, Issue 5, p713
- ISSN
0002-9173
- Publication type
journal article
- DOI
10.1309/AJCPWDEQYCYC92JQ